In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
As private practices close and the number of doctors joining rep-restricted hospital-based and integrated delivery networks of healthcare increases, pharma needs to look at the advantages of mobile marketing to “detail” these hospital-based professionals.
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition.
While pharma brands have made great strides in engaging with people on social media, Shuttlerock CEO Jonny Hendriksen has found that several myths have been perpetuated about translating existing video into shorter, mobile ads.
Fitbit Inc. won a contract with the Singapore government to provide fitness trackers and services to up to one million of the country’s citizens as part of a health initiative that begins in October 2019.
Med Ad News spoke with digital guru Fabio Gratton about the present and future of augmented and virtual reality technologies in pharma and healthcare.
Corindus Vascular Robotics entered into a definitive merger agreement to be acquired by Siemens Healthineers AG for an aggregate purchase price of approximately $1.1 billion.
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.
Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.
With a technology like VR, arguably even more so than in live settings, we can readily tap into multiple learning styles by integrating different types of media into a single experience.
David Lickrish – president, founder and chief executive officer of Highland Therapeutics and Ironshore Therapeutics – spoke with BioSpace about the companies’ Jornay PM (methylphenidate HCL Extended-Release CLL Capsules) and how the new drug fits into the overall ADHD therapeutic market.
People who track their daily steps may not only be more active, they may also be less likely to develop health problems that lead to events like heart attacks or broken bones, a new study suggests.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!
